aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...

More documents

Recommendations

Info

(BII). yvelaze maRali sixSire aRiniSna espaneTSi 26% (33) (BII) da sanfranciskoSi 19% (34) (BII). sloveniis monacemebiT rezistentobis sixSire dabalia – 3,9% (35) (BII). eqspertebi rekomendacias uweven rezistentobis testirebas arT dawyebamde axaldiagnozdasmul pacientebSi (36-38) (BII), sadac igi xelmisawvdomia, xolo SezRuduli resursebis pirobebSi rezistentobaze sentineluri (saguSago) zedamxedvelobis dawesebas. arT dawyeba SesaZlebelia rezistentobaze testirebis gareSe. ixileT danarTi 3 rezistentobis testirebaze damatebiTi informaciisTvis. 4.2 pirveli rigis maarT reJimi rekomendebulia, rom pirveli rigis arT Seicavdes or nukleozid/nukleotidis analog revers transkriftazas inhibitors (nrti anu NRTI) da erT ara-nukleozidis analogis revers transkriptazas inhibitors (anrti anu NNRTI). rekomendebuli dozebisTvis ixileT danarTi 4. cxrili 9 rekomendaciebi pirveli rigis arT Sesaxeb arT reJimi 2 NRTI-s + 1 NNRTI medikamentebis kombinacia ZDV + 3TC + (EFV a or NVP) an TDF + FTC + (EFV a or NVP) an ABC + 3TC + (EFV a or NVP) a. EFV ganixileba, rogorc upiratesi anrti (AI) 4.2.1. nrti komponenti - pirveli rigis arT-s ZiriTadi Semadgeneli nawilia ori nrti-s kombinacia. erT-erTi unda iyos lamivudini (3TC) an emtricitabini (FTC) (39) (AI), xolo meore yvelaze xSirad zidovudinia (ZDV). vinaidan zidovudini pirveli rekomendebuli arv medikamenti iyo, masze uxvi monacemebia dagrovili. - sxva SesaZlo nrti-ebia tenofoviri (TDF) da abakaviri (ABC) 3TC–Tan an FTC–Tan kombinaciaSi. uaxlesi kvlevebi aCveneben TDF/FTC–is kombinaciis mcire upiratesobas ZDV/3TC–Tan SedarebiT, rodesac gamoiyeneba efavirenzTan (EFV) kombinaciaSi (40) (AI). aRniSnuli SesaZloa ganpirobebuli iyos TDF namkurnaleb pacientebSi gverdiTi movlenebis simciriT. saWiroa damatebiTi kvlevebi aRniSnulis dasadastureblad. unda aRiniSnos, rom ABC miRebis dros arsebobs saxifaTo hipersensitiurobis sindromis riski. - TDF da ABC upiratesobaa maTi rezistentobis kargi profili, romelic saSualebas iZleva momavalSi meti nrti-s kombinaciis gamoyenebas. Tumca maT aReniSnebaT seriozuli gverdiTi movlenebi da efeqturobis monacemebic mcirea zidovudinTan SedarebiT (41) (CIII). 34
arv medikamentebi arseboben Semdegi fiqsirebuli dozis kombinaciebis saxiT (anu ori medikamenti 1 tabletSi): - ZDV + 3TC - TDF + FTC - ABC + 3TC - TDF/FTC kombinaciis ABC/3TC kombinaciasTan SedarebiT damatebiTi upiratesobaa dReSi erTxel misaRebi reJimis arseboba. - yvela sxva nrti kombinacias pirveli rigis reJimSi gamoyenebisTvis esaWiroeba safuZvliani mizezi. zogierTi kombinacia ar aris rekomendebuli (42), xolo sxvebs sWirdebaT gverdiTi movlenebis mWidro monitoringi. uaxlesi kvlevebi aCveneben gverdiTi movlenebis maRal sixSires stavudinis (d4T) gamoyenebis dros (40-47) (AI). amis gamo d4T gamoyenebul unda iqnes mxolod im SemTxvevaSi, Tu sxva arCevani ar aris an sxva nrti-ebi ukunaCvenebia. arsebobs nrti-ebis gamoyenebasTan dakavSirebuli ramdenime wesi: - ar gamoiyenoT d-medikamentebis kombinacia (ddI (didanozini), ddC (zalcitabini), d4T). - ar daiwyoT mkurnaloba d-medikamentiT arsebuli neiropaTiis dros. - ar gamoiyenoT ZDV da d4T kombinacia. - ar gamoiyenoT 3TC da FTC kombinacia. 4.2.2. anrti komponenti - saukeTeso monacemebi arsebobs ZDV + 3TC + EFV Sesaxeb (48–50) (AI). aRniSnuli sami medikamentisgan Semdgari kombinacia dReSi orjer misaRebia. igi swrafadmoqmedia - EFV gamoyenebis dros virusuli datvirTva swrafad iklebs pirvel ori kviris ganmavlobaSi, CD4 ricxvis mateba sxva reJimebis dros aRniSnuli matebis msgavsia. Tumca aucilebelia mkurnalobis dawyebamde Tanmxlebi fsiqiatriuli daavadebebis gamoricxva. - nevirapini (NVP) kidev erTi rekomendebuli anrtia, romelic nrti-ebTan kombinaciaSi gamoiyeneba. RviZlis daavadebebis dros maRalia misi toqsiuroba (52) (AI). amis gamo misi gamoyeneba rekomendebulia qalebSi Tu CD4 ricxvi
Page 1 and 2: aiv infeqcia/SidsiT avadmyofTa mkur
Page 3 and 4: sarCevi klinikuri saxelmZRvanelo-re
Page 5 and 6: 3.2.2.cxeleba aiv inficirebulebSi 3
Page 7 and 8: aiv infeqcia/Sidsis fonze ganviTare
Page 9 and 10: done mtkicebulebis siZlieris done (
Page 11 and 12: 1.daavadebis definicia Sidsi abrevi
Page 13 and 14: Sidsi registrirebulia msoflios 216
Page 15 and 16: egistrirebul SemTxveevaTa 79% saqar
Page 17 and 18: adamianis imunodeficitis virusis sa
Page 19 and 20: aiv rnm-is koncentracia plazmaSi mk
Page 21 and 22: SeuZlebelia da gadamwyveti misi dia
Page 23 and 24: persistuli generalizebuli limfadeno
Page 25 and 26: signalis amplifikacia komplementuri
Page 27 and 28: • vizitamde rezistentobis testis
Page 29 and 30: • adamianis papilomavirusi (maxvi
Page 31 and 32: etinitis identifikaciisTvis, rodesa
Page 33: cxrili 8 rekomendaciebi arT dawyebi
Page 37 and 38: aCveneben, rom pirveladi rezistento
Page 39 and 40: - tabletebis Cveneba pacientisTvis
Page 41 and 42: - aqedan gamomdinare, nrti+anrti re
Page 43 and 44: igulisxmeba im medikamentebis kombi
Page 45 and 46: X (arv): testebi, romlebic unda Cat
Page 47 and 48: maRali mgrZnobeloba abakaviri (ABC
Page 49 and 50: transaminazebis elevacia anrti (all
Page 51 and 52: ARV toqsiuroba menejmenti nefrotoqs
Page 53 and 54: xSiri oportonistuli infeqciebia, ma
Page 55 and 56: cxrilebis wakiTxvis magaliTi 1. cxr
Page 57 and 58: damateba2. jandacvis msoflio organi
Page 59 and 60: damateba 4. ZiriTadi informacia ant
Page 62 and 63: damateba 5. mkurnalobis reJimis dac
Page 64 and 65: saerTaSoriso saxeli stavudini (d4T)
Page 66 and 67: mcire mutacia muSaobs kombinaciaSi.
Page 68 and 69: 25. Phillips AN et al. Viral load o
Page 70 and 71: Suppl 2:S171-176. 73. Altice FL, Mo
Page 72 and 73: 122. Koval CE et al. Immune reconst
Page 74 and 75: kandidozi dRe yovel dRe - ko-trimoq
Page 76 and 77: karcinoma (ara SidsTan perikardiuli
Page 78 and 79: o cxeleba o wonaSi kleba o Ramis of
Page 80 and 81: indikatorebi filtvis darRveuli funq
Page 82 and 83: o yvelaze xSirad viTardeba diarea,
Page 84 and 85:
o glukokortikoidebis sistematiuri m
Page 86 and 87:
100 mg/dReSi meore rigis sqemebi am
Page 88 and 89:
o eqspoziciis Sedegad daavadebis ga
Page 90 and 91:
o remisiis miRweva Zalian Znelia da
Page 92 and 93:
qimioTerapiiT (mag : B-ALL reJimi)
Page 94 and 95:
• imunodeficitis mqone pacientebS
Page 96 and 97:
an famcikloviri 500 mg 3-jer dReSi
Page 98 and 99:
• berkitis-tipis limfoma; • naz
Page 100 and 101:
3.2.2. cxeleba aiv inficirebulebSi
Page 102 and 103:
afTozuri wylulebi stomatiti qeiliti
Page 104 and 105:
ganmavlobaSi 2 Tvis manZilze (xelis
Page 106 and 107:
o gamonayari warmodgenilia mravlobi
Page 108 and 109:
20. Chen XM et al. Cryptosporidiosi
Page 110 and 111:
Tavi IV. aiv infeqcia/SidsiT daavad
Page 112 and 113:
inficirebul bavSvebSi (ramdenadac a
Page 114 and 115:
8 igulisxmeba piri, romelsac aReniS
Page 116 and 117:
4.3. daxocili da inaqtivirebuli vaq
Page 118 and 119:
kerebSi A hepatiti erTeuli an mcire
Page 120 and 121:
13 riski maRalia staJirebis periodS
Page 122 and 123:
ganmavlobaSi, xolo SedarebiT ufro s
Page 124 and 125:
4.8. tkipismieri encefalitis vaqcin
Page 126 and 127:
CvenebebiTa da doziT, rogorc imunok
Page 128 and 129:
4.11.2.3. cofis sawinaaRmdego imuno
Page 130 and 131:
ekomendebulia: vaqcina rekomendebul
Page 132 and 133:
8. United States Centers for Diseas
Page 134 and 135:
aiv infeqcia/Sidsis antiretrovirusu
Page 136 and 137:
5. mkurnaloba a) rekomendebuli pirv
Page 138 and 139:
aiv infeqcia/SidsiT daavadebuli bav
Page 140 and 141:
joxiseburi TiTebi. Tumca wlebis man
Page 142 and 143:
* saWiroa arv preparatebis bavSvebi
Page 144 and 145:
laboratoriuli monacemebis kontroli
Page 146 and 147:
Tirkmlis funqciuri sinjebi, gulmker
Page 148 and 149:
aiv infeqcia/Sidsis fonze ganviTare
Page 150 and 151:
Page 152 and 153:
6. reabilitacia da dakvirveba monit
Page 154 and 155:
kandidozuri ezofagitis SemTxvevebSi
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
martivi herpesvirusuli infeqciis mZ
Page 170 and 171:
meTodiT, sisxlis saerTo analizi, Rv
Page 172 and 173:
)gamomricxavi _ aiv infeqcia/Sidsis
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
aiv infeqcia/SidsiT avadmyofebSi B
Page 188 and 189:
dinamikaSi dakvirveba CD4≥500/mm
Page 190 and 191:
HBV mkurnalobis efeqturoba HBeAg (+
Page 192 and 193:
) gamomricxavi - aiv infeqcia/Sidsi
Page 194 and 195:
pegilirebuli interferonis da ribavi
Page 196 and 197:
i CD4 X X X X X X X X X TSH X X X H
Page 198 and 199:
)gamomricxavi - aiv infeqcia/Sidsis
Page 200 and 201:
pirveli rigis antituberkulozuri med
Page 202:
testebi: • sisxlis saerTo analizi
show all

aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...

Create successful ePaper yourself

Delete template?

Save as template?